Beacon Equity issues Technical Trading Overview for Discovery Laboratories Inc.
The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
(EMAILWIRE.COM, September 24, 2009 ) DALLAS, Texas - BeaconEquity.com announces an investment report featuring biotechnology company Discovery Laboratories Inc. (Nasdaq: DSCO).
The investment report on Discovery Laboratories Inc. (Nasdaq: DSCO) should be of particular interest to other biotechnology companies: Abbott Laboratories (NYSE: ABT), Forest Laboratories Inc. (NYSE: FRX) and Amgen Inc. (Nasdaq: AMGN).
It is available at: http://www.beaconequity.com/i/DSCO
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Discovery Laboratories Inc. (DSCO) is a biotechnology company engaged in the development of novel Surfactant Replacement Therapies (SRTs) for the treatment of respiratory disorders and disease. The Company's product platform addresses respiratory deficiencies and disease, including respiratory distress syndrome (RDS), bronchopulmonary dysplasia (BPD), acute respiratory failure (ARF) and acute lung injury (ALI). The Company's precision-engineered, peptide-containing pulmonary surfactant technology mimics pulmonary surfactant functions in humans.
Message Board Search for DSCO: http://www.boardcentral.com/boards/DSCO
In the report, the analyst notes:
“Following rapid growth rates from 2004 to 2008, drug sales of respiratory-related conditions is expected to reach $23 billion by 2018, according to The Datamonitor Group; the most recent statistics for the global market potential of the Company's KL4 Surfactant drug therapy could be administered to approximately 45,000 children suffering from RDS in the United States - outside the United States, the potential market could reach more than 100,000.
“If approved by the U.S. Food and Drug Administration (FDA), the market for the Company's drug candidate Surfaxin could reach more than $1 billion at its market saturation. Surfaxin has cleared phase III clinical trials, with the prospects of reaching commercialization reaching approximately 90% following final approval from the FDA.”
To read the entire report visit: http://www.beaconequity.com/i/DSCO
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
The investment report on Discovery Laboratories Inc. (Nasdaq: DSCO) should be of particular interest to other biotechnology companies: Abbott Laboratories (NYSE: ABT), Forest Laboratories Inc. (NYSE: FRX) and Amgen Inc. (Nasdaq: AMGN).
It is available at: http://www.beaconequity.com/i/DSCO
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Discovery Laboratories Inc. (DSCO) is a biotechnology company engaged in the development of novel Surfactant Replacement Therapies (SRTs) for the treatment of respiratory disorders and disease. The Company's product platform addresses respiratory deficiencies and disease, including respiratory distress syndrome (RDS), bronchopulmonary dysplasia (BPD), acute respiratory failure (ARF) and acute lung injury (ALI). The Company's precision-engineered, peptide-containing pulmonary surfactant technology mimics pulmonary surfactant functions in humans.
Message Board Search for DSCO: http://www.boardcentral.com/boards/DSCO
In the report, the analyst notes:
“Following rapid growth rates from 2004 to 2008, drug sales of respiratory-related conditions is expected to reach $23 billion by 2018, according to The Datamonitor Group; the most recent statistics for the global market potential of the Company's KL4 Surfactant drug therapy could be administered to approximately 45,000 children suffering from RDS in the United States - outside the United States, the potential market could reach more than 100,000.
“If approved by the U.S. Food and Drug Administration (FDA), the market for the Company's drug candidate Surfaxin could reach more than $1 billion at its market saturation. Surfaxin has cleared phase III clinical trials, with the prospects of reaching commercialization reaching approximately 90% following final approval from the FDA.”
To read the entire report visit: http://www.beaconequity.com/i/DSCO
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Contact Information:
Beacon Equity
Jeff Bishop
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
Beacon Equity
Jeff Bishop
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
|
Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International Equityallianceir.com Penny Stocks to Watch Sign up for hot penny stock picks Gains of 500%+ possible! Premiumstockpicks.com/landing/ Your text Ads & PR Text Ads plus unlimited press releases, One release featured/Day for only $575 per month. Read more on Text Ads & PR Your text Ads Here! Text Ads are only $289 per month. Ads are placed same day. More on Text Ads Advertising |